In a prospective longitudinal study of advanced BC patients, the concordance of HER2 status between the primary tumor and CTCs was 86% at baseline and 82% during treatment, with 18% of patients that acquired HER2 overexpression on CTCs after anti-HER2 treatment. This evidence concerns the gene ERBB2 and breast cancer.